Most linked-to pages

Showing below up to 50 results in range #101 to #150.

101. Gleevec (Imatinib)‏‎ (2 links)
102. High-dose PBT showed a median OS of 65.6 months for patients with radiation necrosis, and 26.9 months for patients without radiation necrosis in specific studies‏‎ (2 links)
103. Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM.‏‎ (2 links)
104. Historical controls suggest a median overall survival of 20-35% at 12 months for similar populations.‏‎ (2 links)
105. Historical mOS for similar patient population using lomustine is 7.2 months‏‎ (2 links)
106. Hyperthermia‏‎ (2 links)
107. ICT-107‏‎ (2 links)
108. ICT-107 (Tumor-associated Antigen Vaccine)‏‎ (2 links)
109. Impressive 25.3 months in a study combining vaccine with dose-intense temozolomide.‏‎ (2 links)
110. Improved PFS observed with PBT, specific rates vary by study‏‎ (2 links)
111. Increases observed in specific combination trials, such as Irinotecan with Bevacizumab‏‎ (2 links)
112. Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies.‏‎ (2 links)
113. MDNA55‏‎ (2 links)
114. Median overall survival for GBM typically ranges around 16 months with standard treatment.‏‎ (2 links)
115. Median overall survival with standard treatment ranges around 15-17 months for newly diagnosed GBM‏‎ (2 links)
116. Median progression-free survival with standard treatments is about 6-9 months for GBM‏‎ (2 links)
117. Metformin‏‎ (2 links)
118. Metronomic Low-Dose Temozolomide (TMZ)‏‎ (2 links)
119. Metronomic low dose temozolomide (TMZ)‏‎ (2 links)
120. Next-Generation CAR T-Cell Therapy for GBM‏‎ (2 links)
121. Not directly specified; historical control data needed for comprehensive comparison‏‎ (2 links)
122. Not directly specified; ongoing studies aim to clarify Carboplatin's impact on survival in recurrent glioma‏‎ (2 links)
123. Not fully established from available data‏‎ (2 links)
124. Not specified; however, survival six months after recurrence was used as a primary measure in comparative studies with Avastin‏‎ (2 links)
125. Not specified in the provided context‏‎ (2 links)
126. Optune‏‎ (2 links)
127. Optune (Optune Gio® for newer version)‏‎ (2 links)
128. Pending further clinical trials‏‎ (2 links)
129. Pending further clinical trials and data‏‎ (2 links)
130. Pending review of recent clinical trials and comparative studies‏‎ (2 links)
131. Phase III ACT IV trial did not show a significant increase in OS; however, a Phase II trial (ReACT) in recurrent GBM showed improved outcomes with bevacizumab‏‎ (2 links)
132. Phase II trial showed a significant improvement in PFS, particularly for HLA-A2 positive patients with methylated MGMT, showing a median PFS of 24.1 months vs. 8.5 months in the control group.‏‎ (2 links)
133. Platinum Compounds‏‎ (2 links)
134. Procarbazine‏‎ (2 links)
135. Radiation dermatitis, temporary alopecia, radiation otitis, radiation necrosis (more prevalent in PBT group)‏‎ (2 links)
136. Ranges from 26 to 44% with different schedules; 61% PFS-6 with the best results obtained using a specific dosing schedule‏‎ (2 links)
137. ReACT trial showed a 6-month PFS of 28% for the rindopepimut group compared to 16% for the control‏‎ (2 links)
138. SL-701‏‎ (2 links)
139. SL-701 (Immunotherapy Vaccine)‏‎ (2 links)
140. Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments‏‎ (2 links)
141. Stage 1 median overall survival was 11.0 months with a 12-month OS rate of 44%. Stage 2 showed a median OS of 11.7 months with a 12-month OS rate of 50%, suggesting an improvement over historical data.‏‎ (2 links)
142. Standard radiation therapy PFS rates are lower compared to PBT‏‎ (2 links)
143. Standard treatments for GBM typically result in a median overall survival of 14-17 months‏‎ (2 links)
144. Standard treatments offer a median PFS of about 6.9 months‏‎ (2 links)
145. Standard treatments offer a median progression-free survival of about 6.9 months.‏‎ (2 links)
146. Typically, tumors recur within 6 months of standard treatment.‏‎ (2 links)
147. Typically around 6-7 months for standard GBM treatments.‏‎ (2 links)
148. Under investigation; early results promising, especially in combination therapies‏‎ (2 links)
149. Variable across studies‏‎ (2 links)
150. Varied; one study showed median OS of 41.1 months with vaccine and temozolomide, and another indicated 30.3 months with vaccine and basiliximod.‏‎ (2 links)